Clinical trials: LAM
HIV Infection
Safety and Efficacy Study of Switching From Epzicom to Truvada
This protocol describes a prospective, randomized, open-label, multicenter study to evaluate the safety and efficacy of switching from fixed dose abacavir (ABC)/lamivudine (3TC) to fixed dose emtricitabine (FTC)/tenofovir…
- Trial name
- SWIFT (NCT00724711)
- Testing
- emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), abacavir (ABC)/lamivudine (3TC)
- Where
- 80 sites in United States, Canada and 1 more
- Volunteers
- 312 people
- Sponsor
- Gilead Sciences
HIV Infections
Adipose Tissue After Switch to Doravirine
Integrase-strand-transfer-inhibitors (INSTIs) based regimens have been associated with body weight gain and increase in total body adipose tissue (AT).
- Trial name
- ADDORE (NCT05477407)
- Testing
- Switch from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
HIV Infections
A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs
The purpose of this study is to compare the safety of didanosine plus stavudine plus nelfinavir (NLF) with that of zidovudine plus lamivudine plus NLF.
- Trial name
- NCT00002411
- Testing
- Nelfinavir mesylate, Lamivudine, Stavudine
- Where
- 32 sites in United States
- Sponsor
- Bristol-Myers Squibb
HIV-1-infection
Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully
The main objective of the MODULO trial is to compare (non-inferiority) the capacity of DOR/3TC and DTG/3TC two-drug regimens of maintain virological success at W48 in people living with HIV virus ( PLWH) with suppressed HIV…
- Trial name
- MODULO (NCT06774872)
- Testing
- Doravirine 100Mg Tab and Lamivudine 300 Mg Tab, Dolutegravir 50mg Tab and Lamivudine 300 Mg Tab
- Where
- France
- Volunteers
- 408 people
- Sponsor
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Pulmonary Lymphangioleiomyomatosis
The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
Lymphangioleiomyomatosis (LAM) is a rare lung disease that mostly affects women of childbearing age. In LAM, abnormal, muscle-like cells begin to grow out of control in the lungs.
- Trial name
- NCT02116712
- Testing
- Saracatinib
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Tony Eissa
HIV, Drug
HIV Drug Resistance Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil
Brazil was the first middle-income country to provide free and universal access to antiretroviral drugs to HIV infected individuals.
- Conditions
- HIV, Drug, Resistance
- Trial name
- NCT04453436
- Testing
- Tenofovir Disoproxil
- Where
- Brazil
- Volunteers
- 2,500 people
- Sponsor
- Federal University of São Paulo
Ebola, HIV/AIDS
Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy
Ebola and HIV are found predominately in the same regions of the world and countries in sub-Saharan Africa are most affected by both diseases. For Ebola, no approved therapies exist.
- Trial name
- RemTLAR (NCT04385719)
- Testing
- Remdesivir
- Where
- Uganda
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Makerere University
Body Weight Changes, Human Immunodeficiency Virus
Doravirine and Weight Gain in Antiretroviral Naive
The purpose of this study is determine whether different antiretroviral therapy (ART) changes the effects on body fat and predict the weight change in Black and Hispanic females.
- Conditions
- Body Weight Changes, Human Immunodeficiency Virus, ART, Obesity
- Trial name
- DAWN (NCT05457530)
- Testing
- DOR/3TC/TDF, DOR + FTC/TAF, BIC/FTC/TAF
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Prism Health North Texas
HIV Infections
A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment
The purpose of this study is to determine the value of changing anti-HIV medications in children with progressive HIV disease who have received previous treatment.
- Trial name
- NCT00000902
- Testing
- Ritonavir, Nelfinavir mesylate, Nevirapine
- Where
- 62 sites in United States, Puerto Rico
- Volunteers
- 217 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis B
Lamivudine Plus Adefovir Versus Telbivudine Plus Adefovir in Lamivudine Resistant Chronic Hepatitis B
No study has reported on the comparative effect of continuing lamivudine plus adefovir versus switching to telbivudine plus adefovir in HBeAg-positive lamivudine-refractory chronic hepatitis B patients who have suboptimal…
- Trial name
- NCT01270165
- Testing
- telbivudine
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Yonsei University
Proportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48
Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus Adefovir
Little is known about efficacy of switching to tenofovir monotherapy for lam-resistant chronic hepatitis B patients who achieved a complete virological response to lamivudine plus adefovir.
- Trial name
- NCT03236584
- Testing
- lamivudine plus adefovir combination, Tenofovir Disoproxil Fumarate
- Volunteers
- 76 people
- Sponsor
- Uijeongbu St. Mary Hospital
HIV Infections
Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects
The purpose of Study GS-01-934 was to assess the efficacy and safety of two simplified antiretroviral treatment (ART) regimens in ART-naive, human immunodeficiency virus, type 1 (HIV-1) infected participants.
- Trial name
- NCT00112047
- Testing
- Emtricitabine (FTC), Tenofovir Disoproxil Fumarate (TDF), Efavirenz (EFV)
- Where
- 5 sites in United States
- Volunteers
- 517 people
- Sponsor
- Gilead Sciences
Lymphangioleiomyomatosis (LAM)
COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
The investigators will perform a two-center phase I trial of celecoxib (COX-2 inhibitor) administered at 200mg by mouth daily for 6 months. Up to 12 adult women with LAM will be recruited (between 4-8 at each site).
- Trial name
- COLA (NCT02484664)
- Testing
- Celecoxib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Brigham and Women's Hospital
Hepatitis B, Chronic
Lamivudine and Adefovir Dipivoxil Fixed Dose Combination
This is a phase I study being conducted to support the clinical development program of a FDC product of the nucleoside analogue lamivudine and the nucleotide analogue adefovir dipivoxil.
- Trial name
- NCT01353742
- Testing
- Lamivudine, Adefovir dipivoxil, Fixed dose combination (Lamivudine and Adefovir dipivoxil)
- Where
- Hong Kong
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tuberculosis, Tuberculosis, Pulmonary
Feasibility of a Lateral Flow Urine Lipoarabinomannan (LAM) Test for Diagnosis of Tuberculosis
The purpose of this study is to evaluate the accuracy, diagnostic yield, operational performance, and time to diagnosis of a novel lateral-flow urine lipoarabinomannan (LAM) test in detecting tuberculosis in HIV-infected adults.
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Miliary
- Trial name
- NCT01525134
- Testing
- Alere "Determine" lateral-flow urine lipoarabinomannan assay, Alere "Clearview" ELISA urine LAM assay
- Where
- 2 sites in Uganda
- Volunteers
- 504 people
- Sponsor
- Tuberculosis Clinical Diagnostics Research Consortium
Infection, Human Immunodeficiency Virus
A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers
Lamivudine (3TC) is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and children.
- Trial name
- NCT02634073
- Testing
- Lamivudine, Sorbitol
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Hepatitis B, Chronic
A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
This study will compare the efficacy and safety of 2 different durations of treatment with pegylated interferon (PEG-IFN) alfa-2a in participants with Hepatitis B e Antigen (HBeAg)-negative chronic hepatitis B virus (HBV).
- Trial name
- NCT01095835
- Testing
- Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg, Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg, Lamivudine (LAM)
- Where
- 22 sites in Italy
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany
This is a prospective, non-interventional, multi-center study, in participants with clinical indication of Human Immunodeficiency Virus (HIV)-1 infection.
- Trial name
- URBAN (NCT03754803)
- Testing
- HIV symptom distress module (SDM) questionnaire, HIV treatment satisfaction questionnaire (TSQ)
- Where
- 18 sites in Germany
- Volunteers
- 376 people
- Sponsor
- ViiV Healthcare
Tuberous Sclerosis, Angiolipoma
Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)
This is an open label long term follow up study, open to those subjects who were previously enrolled in"RAD001 Therapy of Angiomyolipomata in Patients with Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis", CCHMC…
- Trial name
- NCT00792766
- Testing
- everolimus (RAD001)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
HIV Infections
A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months
To determine the clinical efficacy of indinavir sulfate or placebo in combination with zidovudine ( AZT ) and lamivudine ( 3TC ) in AIDS patients.
- Trial name
- NCT00000841
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 87 sites in United States, Puerto Rico
- Volunteers
- 1,750 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)